These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 20720502)

  • 21. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
    Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
    Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging.
    Walker MD; Volta M; Cataldi S; Dinelle K; Beccano-Kelly D; Munsie L; Kornelsen R; Mah C; Chou P; Co K; Khinda J; Mroczek M; Bergeron S; Yu K; Cao LP; Funk N; Ott T; Galter D; Riess O; Biskup S; Milnerwood AJ; Stoessl AJ; Farrer MJ; Sossi V
    J Parkinsons Dis; 2014; 4(3):483-98. PubMed ID: 25000966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease.
    Melrose HL; Kent CB; Taylor JP; Dachsel JC; Hinkle KM; Lincoln SJ; Mok SS; Culvenor JG; Masters CL; Tyndall GM; Bass DI; Ahmed Z; Andorfer CA; Ross OA; Wszolek ZK; Delldonne A; Dickson DW; Farrer MJ
    Neuroscience; 2007 Jul; 147(4):1047-58. PubMed ID: 17611037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration.
    Daher JP; Abdelmotilib HA; Hu X; Volpicelli-Daley LA; Moehle MS; Fraser KB; Needle E; Chen Y; Steyn SJ; Galatsis P; Hirst WD; West AB
    J Biol Chem; 2015 Aug; 290(32):19433-44. PubMed ID: 26078453
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Upregulation of the p53-p21 pathway by G2019S LRRK2 contributes to the cellular senescence and accumulation of α-synuclein.
    Ho DH; Seol W; Son I
    Cell Cycle; 2019 Feb; 18(4):467-475. PubMed ID: 30712480
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LRRK2 impairs autophagy by mediating phosphorylation of leucyl-tRNA synthetase.
    Ho DH; Kim H; Nam D; Sim H; Kim J; Kim HG; Son I; Seol W
    Cell Biochem Funct; 2018 Dec; 36(8):431-442. PubMed ID: 30411383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical and brain imaging characteristics in leucine-rich repeat kinase 2-associated PD and asymptomatic mutation carriers.
    Brockmann K; Gröger A; Di Santo A; Liepelt I; Schulte C; Klose U; Maetzler W; Hauser AK; Hilker R; Gomez-Mancilla B; Berg D; Gasser T
    Mov Disord; 2011 Nov; 26(13):2335-42. PubMed ID: 21989859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alzheimer's disease tau is a prominent pathology in LRRK2 Parkinson's disease.
    Henderson MX; Sengupta M; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2019 Nov; 7(1):183. PubMed ID: 31733655
    [TBL] [Abstract][Full Text] [Related]  

  • 29. LRRK2 Kinase Activity Does Not Alter Cell-Autonomous Tau Pathology Development in Primary Neurons.
    Henderson MX; Changolkar L; Trojanowski JQ; Lee VMY
    J Parkinsons Dis; 2021; 11(3):1187-1196. PubMed ID: 33720852
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neuropathology of Parkinson's disease with the R1441G mutation in LRRK2.
    Martí-Massó JF; Ruiz-Martínez J; Bolaño MJ; Ruiz I; Gorostidi A; Moreno F; Ferrer I; López de Munain A
    Mov Disord; 2009 Oct; 24(13):1998-2001. PubMed ID: 19735093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology.
    Mamais A; Manzoni C; Nazish I; Arber C; Sonustun B; Wray S; Warner TT; Cookson MR; Lewis PA; Bandopadhyay R
    Brain Res; 2018 Dec; 1701():75-84. PubMed ID: 30055128
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A rat model of progressive nigral neurodegeneration induced by the Parkinson's disease-associated G2019S mutation in LRRK2.
    Dusonchet J; Kochubey O; Stafa K; Young SM; Zufferey R; Moore DJ; Schneider BL; Aebischer P
    J Neurosci; 2011 Jan; 31(3):907-12. PubMed ID: 21248115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TDP-43 pathology in a patient carrying G2019S LRRK2 mutation and a novel p.Q124E MAPT.
    Ling H; Kara E; Bandopadhyay R; Hardy J; Holton J; Xiromerisiou G; Lees A; Houlden H; Revesz T
    Neurobiol Aging; 2013 Dec; 34(12):2889.e5-9. PubMed ID: 23664753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Leucine-rich repeat kinase 2 associates with lipid rafts.
    Hatano T; Kubo S; Imai S; Maeda M; Ishikawa K; Mizuno Y; Hattori N
    Hum Mol Genet; 2007 Mar; 16(6):678-90. PubMed ID: 17341485
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications.
    Qing H; Wong W; McGeer EG; McGeer PL
    Biochem Biophys Res Commun; 2009 Sep; 387(1):149-52. PubMed ID: 19576176
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lrrk2 and chronic inflammation are linked to pallido-ponto-nigral degeneration caused by the N279K tau mutation.
    Miklossy J; Qing H; Guo JP; Yu S; Wszolek ZK; Calne D; McGeer EG; McGeer PL
    Acta Neuropathol; 2007 Sep; 114(3):243-54. PubMed ID: 17639429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Leucine-rich repeat kinase 2 regulates Sec16A at ER exit sites to allow ER-Golgi export.
    Cho HJ; Yu J; Xie C; Rudrabhatla P; Chen X; Wu J; Parisiadou L; Liu G; Sun L; Ma B; Ding J; Liu Z; Cai H
    EMBO J; 2014 Oct; 33(20):2314-31. PubMed ID: 25201882
    [TBL] [Abstract][Full Text] [Related]  

  • 38. LRRK2 activity does not dramatically alter α-synuclein pathology in primary neurons.
    Henderson MX; Peng C; Trojanowski JQ; Lee VMY
    Acta Neuropathol Commun; 2018 May; 6(1):45. PubMed ID: 29855356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations.
    Sheng Z; Zhang S; Bustos D; Kleinheinz T; Le Pichon CE; Dominguez SL; Solanoy HO; Drummond J; Zhang X; Ding X; Cai F; Song Q; Li X; Yue Z; van der Brug MP; Burdick DJ; Gunzner-Toste J; Chen H; Liu X; Estrada AA; Sweeney ZK; Scearce-Levie K; Moffat JG; Kirkpatrick DS; Zhu H
    Sci Transl Med; 2012 Dec; 4(164):164ra161. PubMed ID: 23241745
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Parkinson's Disease-Associated Mutation LRRK2-G2019S Impairs Synaptic Plasticity in Mouse Hippocampus.
    Sweet ES; Saunier-Rebori B; Yue Z; Blitzer RD
    J Neurosci; 2015 Aug; 35(32):11190-5. PubMed ID: 26269629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.